Description
AG-013726 is an investigational drug being studied by Pfizer. It is currently in early-phase clinical trials (Phase 1) for colorectal cancer. The trials are primarily focused on evaluating its safety and how it is processed by the body (pharmacokinetics) when given in combination with standard treatments like chemotherapy and bevacizumab. The goal is to see if AG-013726 can be safely added to existing therapies for metastatic colorectal cancer, potentially improving outcomes. It is important to note that AG-013726 is not yet approved for use in colorectal cancer or any other condition. Further research is needed to determine its effectiveness and appropriate use.
Mechanism of Action
The specific way AG-013726 works (its mechanism of action) is still being investigated in clinical trials. It is being studied in combination with other standard treatments for metastatic colorectal cancer. The trials aim to assess its safety and how it interacts with these standard therapies.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.